ArticleCancer reports (Hoboken, N.J.)2022

The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1-3 node positive breast cancer.

Yogeshkumar Malam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.